These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 36761744)
21. Identification of a basement membrane-related genes signature with immune correlation in bladder urothelial carcinoma and verification in vitro. Li Y; Xu K; Zhang Y; Mao H; Qiu Q; Yan Z; Liu X; Du Y; Chen Z BMC Cancer; 2023 Oct; 23(1):1021. PubMed ID: 37872487 [TBL] [Abstract][Full Text] [Related]
22. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma. Zhou Q; Yan X; Zhu H; Xin Z; Zhao J; Shen W; Yin W; Guo Y; Xu H; Zhao M; Liu W; Jiang X; Ren C Theranostics; 2021; 11(20):9775-9790. PubMed ID: 34815785 [No Abstract] [Full Text] [Related]
23. Establishment of a risk score model for bladder urothelial carcinoma based on energy metabolism-related genes and their relationships with immune infiltration. Huang C; Li Y; Ling Q; Wei C; Fang B; Mao X; Yang R; Zhang L; Huang S; Cheng J; Liao N; Wang F; Mo L; Mo Z; Li L FEBS Open Bio; 2023 Apr; 13(4):736-750. PubMed ID: 36814419 [TBL] [Abstract][Full Text] [Related]
24. Identification of Tumor Antigens and Immune Subtypes of Esophageal Squamous Cell Carcinoma for mRNA Vaccine Development. Lu T; Xu R; Wang CH; Zhao JY; Peng B; Wang J; Zhang LY Front Genet; 2022; 13():853113. PubMed ID: 35734437 [No Abstract] [Full Text] [Related]
25. Pan-cancer analysis of PLAU indicates its potential prognostic value and correlation with neutrophil infiltration in BLCA. Shi K; Zhou J; Li M; Yan W; Zhang J; Zhang X; Jiang L Biochim Biophys Acta Mol Basis Dis; 2024 Feb; 1870(2):166965. PubMed ID: 38000776 [TBL] [Abstract][Full Text] [Related]
26. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases. He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970 [TBL] [Abstract][Full Text] [Related]
27. MTHFD2 is a potential oncogene for its strong association with poor prognosis and high level of immune infiltrates in urothelial carcinomas of bladder. Zhu L; Liu X; Zhang W; Hu H; Wang Q; Xu K BMC Cancer; 2022 May; 22(1):556. PubMed ID: 35581573 [TBL] [Abstract][Full Text] [Related]
28. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development. Huang X; Tang T; Zhang G; Liang T Mol Cancer; 2021 Mar; 20(1):50. PubMed ID: 33685460 [TBL] [Abstract][Full Text] [Related]
29. Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation. Wang X; Bai Y; Zhang F; Li D; Chen K; Wu R; Tang Y; Wei X; Han P Front Immunol; 2023; 14():955949. PubMed ID: 37006317 [TBL] [Abstract][Full Text] [Related]
30. Screening of Tumor Antigens and Construction of Immune Subtypes for mRNA Vaccine Development in Head and Neck Squamous Cell Carcinoma. Li HX; Liu TR; Tu ZX; Xie CB; Wen WP; Sun W Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671475 [TBL] [Abstract][Full Text] [Related]
31. Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine. Zhong H; Liu S; Cao F; Zhao Y; Zhou J; Tang F; Peng Z; Li Y; Xu S; Wang C; Yang G; Li ZQ Front Immunol; 2021; 12():709986. PubMed ID: 34512630 [TBL] [Abstract][Full Text] [Related]
32. Investigating cellular similarities and differences between upper tract urothelial carcinoma and bladder urothelial carcinoma using single-cell sequencing. Zhang Q; Wang C; Qin M; Ye Y; Mo Y; Meng Q; Yang G; Feng G; Lin R; Xian S; Wei J; Chen S; Wang S; Mo Z Front Immunol; 2024; 15():1298087. PubMed ID: 38903524 [TBL] [Abstract][Full Text] [Related]
33. PRR11 is a prognostic biomarker and correlates with immune infiltrates in bladder urothelial carcinoma. Ni W; Yi L; Dong X; Cao M; Zheng J; Wei Q; Yuan C Sci Rep; 2023 Feb; 13(1):2051. PubMed ID: 36739300 [TBL] [Abstract][Full Text] [Related]
34. TUBA1C is a potential new prognostic biomarker and promotes bladder urothelial carcinoma progression by regulating the cell cycle. Jiang Y; Zhu C; Huang H; Huang G; Fu B; Xi X BMC Cancer; 2023 Aug; 23(1):716. PubMed ID: 37528357 [TBL] [Abstract][Full Text] [Related]
35. Identification of Immune-Related Subtypes and Construction of a Novel Prognostic Model for Bladder Urothelial Cancer. Zhang J; Huang C; Yang R; Wang X; Fang B; Mi J; Yuan H; Mo Z; Sun Y Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36421685 [TBL] [Abstract][Full Text] [Related]
36. Identification of tumor-specific neoantigens and immune clusters of hepatocellular carcinoma for mRNA vaccine development. Li YF; Hou QQ; Zhao S; Chen X; Tang M; Li L J Cancer Res Clin Oncol; 2023 Feb; 149(2):623-637. PubMed ID: 36239794 [TBL] [Abstract][Full Text] [Related]
37. Clinical value of anoikis-related genes and molecular subtypes identification in bladder urothelial carcinoma and Dong Y; Xu C; Su G; Li Y; Yan B; Liu Y; Yin T; Mou S; Mei H Front Immunol; 2023; 14():1122570. PubMed ID: 37275895 [TBL] [Abstract][Full Text] [Related]
38. Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination. You W; Ouyang J; Cai Z; Chen Y; Wu X Front Immunol; 2022; 13():827506. PubMed ID: 35874675 [TBL] [Abstract][Full Text] [Related]
39. Integrated Analysis of Energy Metabolism Signature-Identified Distinct Subtypes of Bladder Urothelial Carcinoma. Zhang F; Liang J; Feng D; Liu S; Wu J; Tang Y; Liu Z; Lu Y; Wang X; Wei X Front Cell Dev Biol; 2022; 10():814735. PubMed ID: 35281080 [No Abstract] [Full Text] [Related]
40. Identification of tumor antigens and immune subtypes of hepatocellular carcinoma for mRNA vaccine development. Lu TL; Li CL; Gong YQ; Hou FT; Chen CW World J Gastrointest Oncol; 2023 Oct; 15(10):1717-1738. PubMed ID: 37969406 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]